'Game-Changer' For Ardelyx As Tenapanor Phase III Is A Hit In IBS-C

Positive data for its irritable bowel syndrome therapy put Ardelyx in a better position for partnering and set it up for a filing next year.

Baseball
Ardelyx knocks Tenapanor out of the park • Source: Shutterstock

Strong data in a second Phase III study of Ardelyx Inc.'s investigational treatment for constipation-predominant irritable bowel syndrome (IBS-C), tenapanor, have put the product back on track, and could prove to be transformational for the company. Shares in the firm were up by more than 48% on NASDAQ on the data, restoring some of the value lost back in May when the first Phase III study T3MPO-1 results underwhelmed investors.

Ardelyx's next steps are to seal licensing deal for the product ahead of a planned NDA filing in the second...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D